Healthcare / Drug Manufacturers - Specialty & GenericTSXV
$0.15
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-1.1M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
5.0x
↓EV/EBITDA
0.9x
↓ROE
16.9%
↑Gross Margin
51.7%
↑Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+15.9%
FCF CAGR
—
FCF margin
6.1%
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.4M · net income $876000.0 · FCF $756000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.4M | $12.4M | $9.8M | $8.1M | $8.0M |
| Net Income | $876000.00 | $876000.00 | $-184000.00 | $-7.0M | $-28.5M |
| EBITDA | $2.4M | $2.4M | $1.4M | $-4.3M | $-6.6M |
| EPS | 0.03 | 0.03 | -0.01 | -0.30 | -1.30 |
| Gross Margin | 51.7% | 51.7% | 49.3% | 32.0% | 24.1% |
| Operating Margin | -5.7% | -5.7% | -13.9% | -73.9% | -116.4% |
| Net Margin | 7.1% | 7.1% | -1.9% | -86.1% | -358.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.58 | 0.62 | 0.22 |
| Current Ratio | 3.49 | 3.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $756000.00 | $756000.00 | $-1.1M | $-4.5M | $-9.7M |
| Returns | |||||
| ROE | 16.9% | 16.9% | -5.4% | -207.8% | -286.0% |
| Valuation | |||||
| P/E | 5.00 | 5.00 | — | — | — |
| EV/EBITDA | 0.90 | 0.90 | 3.07 | — | — |
| P/B | 0.82 | 0.82 | 1.49 | 2.25 | 2.38 |
| Growth & Yield | |||||
| Revenue Growth | 26.4% | 26.4% | 20.3% | 2.3% | — |
| EPS Growth | 400.0% | 400.0% | 96.7% | 76.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-23.7%
EPS terminal req.
$0.01
Spread vs growth
423.7%
5Y implied EPS CAGR
-11.7%
EPS terminal req.
$0.02
Spread vs growth
411.7%
10Y implied EPS CAGR
-1.4%
EPS terminal req.
$0.03
Spread vs growth
401.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → 0.03
Residual
-31.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.